Various non-invasive tools, including imaging-based methods (e.g., tomography-computed [CT], magnetic resonance imaging [MRI], and ultrasonography [USG]) and clinical surrogates indices (e.g., fatty liver index [FLI], hepatic steatosis index [HS], NAFLD liver fat score [NAFLD-LFS], and AST/ALT ratio), have been developed to screen for fatty liver, and minimize the need for biopsy procedures8,11. The gene discussed is GPT; the disease is fatty liver disease.